drugset
drugset / Trial / NCT05513937

Effectiveness and Safety of Combination of Nebivolol and Amlodipine in Hypertensive Patients Versus Each Monotherapy

NCT05513937 ↗

Phase 4 Completed 301 enrolled Menarini International Operations Luxembourg SA
Non-randomizedSequentialOpen-labelTreatment

Summary

Study to assess the anti-hypertensive efficacy and safety of the extemporaneous combination of Nebivolol 5 mg in combination with Amlodipine 5 mg or AML 10 mg in lowering the sitting diastolic BP after 8 weeks of treatment inpatients with uncontrolled BP previously treated with Nebivolol (NEB) or Amlodipine (5 mg) monotherapies for at least 4 weeks.

Timeline

Start
2022-05-12
Primary completion
2022-11-15
Completion
2022-11-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amlodipine Other / unclassified 5 mg Oral
Comparator Amlodipine Other / unclassified 10 mg Oral
Comparator Nebivolol Other / unclassified 5 mg Oral

Indications

hypertensive disorder